Pricing pressure, the reimbursement landscape, eroding margins, low valuations and the tax-friendly political climate are just a few of the factors positioning the life sciences industry for a ramp-up of M&A activity. The climate will be competitive for both buy and sell side prospects, and expert legal advice is critical for companies to be able to seize attractive, strategic opportunities. Thinking about M&A, even as a mere twinkle in your strategic plan? Goodwin can help.
We believe our position to be unique within BigLaw given the collaboration of our life sciences team with our robust private equity, technology and healthcare practices. With our largest and strongest practices working together, Goodwin is exceptionally suited to address whatever the future brings.
We have a full-service life sciences team dedicated to providing practical and tactical advice on the ins and outs of deal value and structure, as well as on counseling clients (both public and private) on the risks and rewards of M&A, on every side of the negotiating table.
Our team members are not just expert in the art of M&A, but also have their fingers on the pulse of the unique risks and challenges faced by life sciences industry participants, such as drug safety and efficacy, clinical trial and commercialization matters, scientific validity, IP protection and life cycle management, pricing and reimbursement, as well as regulatory approval and oversight. This specialized experience helps us to develop and implement creative strategies to maximize value and positioning for our clients.
Our team represents:
- serial strategic acquirors and financial sponsors;
- companies in search of the occasional but transformative deal;
- companies looking for an exit; and
- companies who find themselves the recipient of unsolicited overtures.
We have also have team members who regularly advise special committees, individual board or management members, strategic investors and investment bankers in various roles in the M&A space.
This sophisticated team offers engagements for deals of all levels of complexity – from traditional mergers, stock and asset purchases, and tender or exchange offers, to complex cross-border structures, spin or carve-out transactions and strategic option-style deals. We also specialize in advising on shareholder activism, proxy contests, corporate restructurings, takeover defense and liability risk. No question too small, no issue too difficult – we’re here to help.
